NMS-03597812

Ph I Study of NMS-03597812 in Adult Patients With Relapsed or Refractory Multiple Myeloma

What's the purpose of the trial?

This is a Phase I, first-in-human (FIH), open-label, non-randomized, multi-center study to explore the safety, tolerability, pharmacokinetics and preliminary antitumor activity of NMS-03597812 in adult patients with RRMM who have exhausted standard treatment options that are expected to provide meaningful clinical benefit or for whom standard therapy is considered unsuitable.

Trial status

Accepting patients

Phase
Phase 1
Enrollment
65
Last Updated
2 weeks ago
Am I Eligible

Participating Centers

There are 4 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Dexamethasone
  • NMS-03597812

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

NMS-03597812

Not yet accepting

NMS-03597812

Not yet accepting

NMS-03597812 + Dexamethasone

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.